https://scholars.lib.ntu.edu.tw/handle/123456789/582002
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lin C.-L. | en_US |
dc.contributor.author | JIA-HORNG KAO | en_US |
dc.date.accessioned | 2021-09-04T06:11:47Z | - |
dc.date.available | 2021-09-04T06:11:47Z | - |
dc.date.issued | 2013 | - |
dc.identifier.issn | 0929-6646 | - |
dc.identifier.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-84879158955&doi=10.1016%2fj.jfma.2013.02.001&partnerID=40&md5=f84ff6e611c965cc84945f22ada00ebc | - |
dc.identifier.uri | https://scholars.lib.ntu.edu.tw/handle/123456789/582002 | - |
dc.description.abstract | Baseline and on-treatment hepatitis B viral factors are reported to affect treatment responses. A lower baseline hepatitis B virus (HBV) DNA level is a strong predictor of the response to antiviral therapy. HBV genotype A/B patients have better responses to interferon-based therapy than those with genotypes C/D. Regarding the association of HBV mutants with responses to antiviral therapy, current evidence is limited. On-treatment viral suppression is the most important predictor of response to nucleoside analogs. On-treatment hepatitis B surface antigen decline is significantly associated with response to pegylated interferon. In the future, individualized therapy should be based on treatment efficacy, adverse effects, baseline and on-treatment predictors of antiviral therapy. ? 2012, Elsevier Taiwan LLC & Formosan Medical Association. | - |
dc.relation.ispartof | Journal of the Formosan Medical Association | - |
dc.subject | Antiviral therapy; Chronic hepatitis B; Hepatitis B virus DNA; Nucleos(t)ide analogs; Pegylated interferon; Quantitative HBsAg | - |
dc.subject.classification | [SDGs]SDG3 | - |
dc.subject.other | adefovir; adefovir dipivoxil; alanine aminotransferase; alpha interferon; creatinine; entecavir; hepatitis B surface antigen; lamivudine; peginterferon alpha; peginterferon alpha2a; peginterferon alpha2b; telbivudine; tenofovir disoproxil; virus DNA; antiviral resistance; antiviral therapy; clinical effectiveness; competitive inhibition; creatinine blood level; disease association; disease exacerbation; drug efficacy; drug half life; genotype; hepatitis B; Hepatitis B virus; human; liver cirrhosis; monotherapy; mutational analysis; nephrotoxicity; predictive value; review; risk factor; seroconversion; side effect; treatment duration; treatment response; viremia; virus strain; Antiviral Agents; DNA, Viral; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon-alpha; Lamivudine; Polyethylene Glycols; Recombinant Proteins | - |
dc.title | Hepatitis B viral factors and treatment responses in chronic hepatitis B | en_US |
dc.type | Review | en |
dc.identifier.doi | 10.1016/j.jfma.2013.02.001 | - |
dc.identifier.pmid | 23787007 | - |
dc.identifier.scopus | 2-s2.0-84879158955 | - |
dc.relation.pages | 302-311 | - |
dc.relation.journalvolume | 112 | - |
dc.relation.journalissue | 6 | - |
item.fulltext | no fulltext | - |
item.cerifentitytype | Publications | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
item.grantfulltext | none | - |
item.openairetype | Review | - |
crisitem.author.dept | Clinical Medicine | - |
crisitem.author.dept | Internal Medicine-NTUH | - |
crisitem.author.orcid | 0000-0002-2442-7952 | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
Appears in Collections: | 臨床醫學研究所 |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.